NYSE:BHVNBiotechs
How Legal Challenges Over Drug Pipeline Disclosures at Biohaven (BHVN) Have Changed Its Investment Story
Biohaven Ltd. recently reported a net loss of US$198.15 million for the second quarter of 2025, with several law firms announcing class action lawsuits alleging the company made misleading statements about its drug pipeline's regulatory prospects and efficacy.
This wave of legal challenges comes after setbacks such as the FDA's rejection of troriluzole and withdrawal of a European application, raising questions about the reliability of Biohaven's past communications to investors.
We'll...